How to ride the second Chinese biosimilar wave
This article was originally published in Scrip
Today, 40% of China’s recombinant biologic product sales come from biosimilars, which have enjoyed a 25-30% compound annual growth rate (CAGR) over the past 10 years, led by a group of domestic products. What should multinational companies consider when evaluating the biosimilar market in China, and what is the best entry strategy?
Register for our free email digests: